Vivitrol | Addiction Professional Magazine Skip to content Skip to navigation

Vivitrol

Medical director's refrain to patients: 'I don't want to go to your funeral'

September 21, 2018  |  Gary A. Enos, Editor
article
The Mountainside treatment facility in Connecticut is making early inroads with injectable buprenorphine as another option for blocking patients' opioid receptors.

Data show too few youths receive medication for opioid use disorders

September 11, 2018  |  Gary A. Enos, Editor
news
A new study indicates that only about one in four young people with opioid use disorders receives one of the approved medications as part of treatment.

Study: Methadone, buprenorphine after overdose improve survival rates

July 10, 2018  |  Alison Knopf, Contributing Writer
article
A Massachusetts study found that opioid overdose survivors who received methadone or buprenorphine following an overdose showed reduced deaths from subsequent overdoses.

FDA approves non-opioid for opioid withdrawal symptoms

May 17, 2018  |  Gary A. Enos, Editor
news
The Food and Drug Administration has approved the first non-opioid medication for the treatment of painful opioid withdrawal symptoms.

Separate unit for opioid disorder treatment builds fellowship

May 7, 2018  |  Gary A. Enos, Editor
article
Caron Treatment Centers responded to patient concerns about isolation by establishing a treatment unit devoted exclusively to opioid use disorders.

Study explores challenge of initiating patient on injectable naltrexone

April 17, 2018  |  Gary A. Enos, Editor
article
New research offers hope for those who might assume it is too difficult to transition an opioid-dependent patient to injectable naltrexone in a community-based setting.

First non-opioid to treat withdrawal clears key hurdle

April 13, 2018  |  Alison Knopf, Contributing Writer
article
An advisory committee to the Food and Drug Administration (FDA) is recommending approval of lofexidine, which would offer an alternative to opioid medications for treatment of opioid withdrawal symptoms.

SCE: Be open to evidence-based treatment

March 9, 2018  |  Julie Miller, Editor in Chief
article
Experts speaking in Chicago at the Summit For Clinical Excellence, The Opioid Crisis: Strategies for Treatment and Recovery covered a number of treatment modalities that clinicians might not be embracing just yet.

Study offers reasons why alcohol medication adherence poses challenge

February 15, 2018  |  Gary A. Enos, Editor
article
Research reveals several factors that influence the ability of patients with an alcohol use disorder to stay on a daily medication regimen, including intense cravings and a weekend danger.

Drug studies' results make case for access to all opioid dependence medications

November 16, 2017  |  Gary A. Enos, Editor
article
Recent efficacy and safety studies found comparable and encouraging results for buprenorphine and injectable naltrexone in the treatment of opioid dependence.

FDA clears electrical device to combat opioid withdrawal

November 15, 2017  |  Gary A. Enos, Editor
news
The Food and Drug Administration (FDA) today announced that an electrical stimulation device attached to the ear can be marketed for the treatment of symptoms of opioid withdrawal.

Hospital boosts opioid patients' rapid access to medication

November 14, 2017  |  Gary A. Enos, Editor
article
The experience of Boston Medical Center bolsters evidence that hospitalized patients with opioid use disorders can be successfully initiated on medication before discharge.

Pages

Subscribe to Vivitrol